CYP2C19 polymorphism in Iranian patient receiving Clopidogrel

We investigated the pharmacogenetic effects of CYP2C19 polymorphisms in a group of Iranian patients with cardiovascular diseases who were on clopidogrel treatment. One hundred and eighteen Iranian patients receiving implants of coronary stents were selected, in whom the CYP2C19 681G>A polymorphism was analyzed by Restriction Fragment Length Polymorphism (RFLP)-based PCR using Sma I. Seventy-six patients with CYP2C19 (1*1*), 39 patients with CYP2C19 (1*2*), and 3 patients with CYP2C19 (2*2*) were identified. The mean serum clopidogrel concentration in patients with CYP2C19 (1*2*) polymorphism was significantly lower than the CYP2C19 (1*1*) group. However, because of the limited number of the patients in the CYP2C19 (2*2*) group, the result was not fully reliable. The results suggested that patients with CYP2C19 (1*2*) might need a higher dose of clopidegrel than that administered to patients without this polymorphism and a CYP2C19 polymorphism test could be useful in determining the dose of clopidogrel to be administered.